Published in PLoS One on May 14, 2009
Viral quasispecies evolution. Microbiol Mol Biol Rev (2012) 2.69
Mutability dynamics of an emergent single stranded DNA virus in a naïve host. PLoS One (2014) 1.25
A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape. PLoS Pathog (2010) 1.08
Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections. PLoS Pathog (2009) 1.05
Structure of foot-and-mouth disease virus mutant polymerases with reduced sensitivity to ribavirin. J Virol (2010) 1.01
Pathways to extinction: beyond the error threshold. Philos Trans R Soc Lond B Biol Sci (2010) 0.97
Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nat Rev Genet (2015) 0.93
Deletion mutants of VPg reveal new cytopathology determinants in a picornavirus. PLoS One (2010) 0.87
Concomitant lethal mutagenesis of human immunodeficiency virus type 1. J Mol Biol (2012) 0.84
Tempo and mode of inhibitor-mutagen antiviral therapies: a multidisciplinary approach. Proc Natl Acad Sci U S A (2011) 0.83
Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis. PLoS One (2013) 0.81
Mutagenesis-mediated virus extinction: virus-dependent effect of viral load on sensitivity to lethal defection. PLoS One (2012) 0.80
Arenaviruses and lethal mutagenesis. Prospects for new ribavirin-based interventions. Viruses (2012) 0.79
Lethal mutagenesis of foot-and-mouth disease virus involves shifts in sequence space. J Virol (2011) 0.78
Mutagenesis-mediated decrease of pathogenicity as a feature of the mutant spectrum of a viral population. PLoS One (2012) 0.77
Mutagenic Effects of Ribavirin on Hepatitis E Virus-Viral Extinction versus Selection of Fitness-Enhancing Mutations. Viruses (2016) 0.76
Effects of ribavirin on the replication and genetic stability of porcine reproductive and respiratory syndrome virus. BMC Vet Res (2015) 0.75
New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents. Infect Drug Resist (2010) 0.75
Sensitivity of a ribavirin resistant mutant of hepatitis C virus to other antiviral drugs. PLoS One (2013) 0.75
Epistatic Interactions within the Influenza A Virus Polymerase Complex Mediate Mutagen Resistance and Replication Fidelity. mSphere (2017) 0.75
Rapid evolution of RNA genomes. Science (1982) 14.76
Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature (2005) 6.78
Mutation rates among RNA viruses. Proc Natl Acad Sci U S A (1999) 6.37
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med (2000) 5.73
RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A (2001) 5.21
National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002. Hepatology (2002) 5.16
Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med (2008) 4.12
A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci U S A (2003) 3.68
Virus dynamics and drug therapy. Proc Natl Acad Sci U S A (1997) 3.63
Time to hit HIV, early and hard. N Engl J Med (1995) 3.53
Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLoS Pathog (2005) 3.41
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology (2008) 3.14
Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J Virol (1990) 3.11
Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture. Virology (1983) 3.04
Engineering attenuated virus vaccines by controlling replication fidelity. Nat Med (2008) 3.01
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature (2004) 2.74
Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol (1995) 2.68
Exponential increases of RNA virus fitness during large population transmissions. Proc Natl Acad Sci U S A (1995) 2.60
Viral error catastrophe by mutagenic nucleosides. Annu Rev Microbiol (2004) 2.58
Structure of foot-and-mouth disease virus RNA-dependent RNA polymerase and its complex with a template-primer RNA. J Biol Chem (2004) 2.48
Nucleotide sequence heterogeneity of the RNA from a natural population of foot-and-mouth-disease virus. Gene (1980) 2.44
Genetic lesions associated with Muller's ratchet in an RNA virus. J Mol Biol (1996) 2.41
Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J Biol Chem (2005) 2.40
Production of guanidine-resistant and -dependent poliovirus mutants from cloned cDNA: mutations in polypeptide 2C are directly responsible for altered guanidine sensitivity. J Virol (1986) 2.33
Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther (1990) 2.26
Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J Virol (2000) 2.26
Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS (2002) 2.21
Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology (2003) 2.14
Heterogeneity of porcine reproductive and respiratory syndrome virus: implications for current vaccine efficacy and future vaccine development. Vet Microbiol (2000) 2.14
A comparison of viral RNA-dependent RNA polymerases. Curr Opin Struct Biol (2005) 2.14
Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol (2005) 2.00
Multiple molecular pathways for fitness recovery of an RNA virus debilitated by operation of Muller's ratchet. J Mol Biol (1999) 2.00
Efficient virus extinction by combinations of a mutagen and antiviral inhibitors. J Virol (2001) 1.86
Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem (2001) 1.85
The metabolism of ribavirin in erythrocytes and nucleated cells. Int J Biochem (1990) 1.77
RNA virus evolution and the control of viral disease. Prog Drug Res (1989) 1.74
Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol (2005) 1.74
Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother (1986) 1.72
Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology (2007) 1.70
Ribavirin--current status of a broad spectrum antiviral agent. Expert Opin Pharmacother (2001) 1.70
Suppression of viral infectivity through lethal defection. Proc Natl Acad Sci U S A (2005) 1.62
Evolutionary transition toward defective RNAs that are infectious by complementation. J Virol (2004) 1.61
Ribavirin's antiviral mechanism of action: lethal mutagenesis? J Mol Med (Berl) (2001) 1.59
Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J Virol (2003) 1.58
Metabolism and antiviral activity of ribavirin. Virus Res (2005) 1.57
Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J Virol (2006) 1.56
Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol (2002) 1.52
The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology (2003) 1.50
Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J Virol (2001) 1.50
Incorporation fidelity of the viral RNA-dependent RNA polymerase: a kinetic, thermodynamic and structural perspective. Virus Res (2005) 1.48
Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol (2003) 1.47
Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology (2003) 1.44
Sequential structures provide insights into the fidelity of RNA replication. Proc Natl Acad Sci U S A (2007) 1.37
Quasispecies dynamics and RNA virus extinction. Virus Res (2005) 1.35
An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem Pharmacol (1997) 1.34
Quasispecies, error catastrophe, and the antiviral activity of ribavirin. Virology (2002) 1.28
Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J Virol (2005) 1.28
Preextinction viral RNA can interfere with infectivity. J Virol (2004) 1.26
Ribavirin cures cells of a persistent infection with foot-and-mouth disease virus in vitro. J Virol (1987) 1.18
Insights into RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants. J Mol Biol (2007) 1.17
Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses (1994) 1.10
Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol (2007) 1.10
Oral ribavirin therapy for subacute sclerosing panencephalitis. J Infect Dis (1989) 1.08
Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology (2007) 1.07
Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Antimicrob Agents Chemother (1993) 1.07
Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. J Viral Hepat (2004) 1.07
Hidden virulence determinants in a viral quasispecies in vivo. J Virol (2008) 1.06
Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. Biochemistry (2003) 1.06
Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? Drug Resist Updat (2004) 1.02
Sindbis virus mutants resistant to mycophenolic acid and ribavirin. Virology (1987) 1.00
Dynamics of mutation and recombination in a replicating population of complementing, defective viral genomes. J Mol Biol (2006) 1.00
Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases. Handb Exp Pharmacol (2009) 1.00
Resistance to extinction of low fitness virus subjected to plaque-to-plaque transfers: diversification by mutation clustering. J Mol Biol (2002) 0.98
Action of mutagenic agents and antiviral inhibitors on foot-and-mouth disease virus. Virus Res (2005) 0.96
Repeated bottleneck transfers can lead to non-cytocidal forms of a cytopathic virus: implications for viral extinction. J Mol Biol (2007) 0.90
Invariant aphthovirus consensus nucleotide sequence in the transition to error catastrophe. Infect Genet Evol (2005) 0.90
Genetic variability: the key problem in the prevention and therapy of RNA-based virus infections. Med Res Rev (2003) 0.90
Dynamics of picornavirus RNA replication within infected cells. J Gen Virol (2008) 0.90
Molecular characterization of a dual inhibitory and mutagenic activity of 5-fluorouridine triphosphate on viral RNA synthesis. Implications for lethal mutagenesis. J Mol Biol (2008) 0.89
Ribavirin: is it a mutagen for hepatitis C virus? Gastroenterology (2007) 0.87
Future prospects for the treatment of rapidly evolving viral pathogens: insights from evolutionary biology. Expert Opin Biol Ther (2008) 0.82
Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients. AIDS Res Hum Retroviruses (2002) 0.78
The role of ribavirin-induced mutagenesis in HCV therapy: a concept or a fact? Hepatology (2003) 0.78
Biological and biomedical implications of the co-evolution of pathogens and their hosts. Nat Genet (2002) 4.42
Structure of foot-and-mouth disease virus RNA-dependent RNA polymerase and its complex with a template-primer RNA. J Biol Chem (2004) 2.48
Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology (2003) 1.76
Suppression of viral infectivity through lethal defection. Proc Natl Acad Sci U S A (2005) 1.62
Evolutionary transition toward defective RNAs that are infectious by complementation. J Virol (2004) 1.61
Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J Virol (2003) 1.58
Effect of alternating passage on adaptation of sindbis virus to vertebrate and invertebrate cells. J Virol (2005) 1.57
Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J Virol (2006) 1.56
The structure of a protein primer-polymerase complex in the initiation of genome replication. EMBO J (2006) 1.54
Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology (2003) 1.44
Sequential structures provide insights into the fidelity of RNA replication. Proc Natl Acad Sci U S A (2007) 1.37
High mutation rates, bottlenecks, and robustness of RNA viral quasispecies. Gene (2005) 1.31
Resistance of virus to extinction on bottleneck passages: study of a decaying and fluctuating pattern of fitness loss. Proc Natl Acad Sci U S A (2003) 1.27
Preextinction viral RNA can interfere with infectivity. J Virol (2004) 1.26
Structural insights into replication initiation and elongation processes by the FMDV RNA-dependent RNA polymerase. Curr Opin Struct Biol (2009) 1.22
Duration and fitness dependence of quasispecies memory. J Mol Biol (2002) 1.18
Insights into RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants. J Mol Biol (2007) 1.17
Mutant viral polymerase in the transition of virus to error catastrophe identifies a critical site for RNA binding. J Mol Biol (2005) 1.13
Evidence for quasispecies distributions in the human hepatitis A virus genome. Virology (2003) 1.10
A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape. PLoS Pathog (2010) 1.08
Hidden virulence determinants in a viral quasispecies in vivo. J Virol (2008) 1.06
Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome. PLoS One (2012) 1.06
Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections. PLoS Pathog (2009) 1.05
Molecular basis for a lack of correlation between viral fitness and cell killing capacity. PLoS Pathog (2007) 1.04
Ribavirin can be mutagenic for arenaviruses. J Virol (2011) 1.03
Viral genome segmentation can result from a trade-off between genetic content and particle stability. PLoS Genet (2011) 1.03
Arenavirus genetic diversity and its biological implications. Infect Genet Evol (2009) 1.03
Initial fitness recovery of HIV-1 is associated with quasispecies heterogeneity and can occur without modifications in the consensus sequence. PLoS One (2010) 1.02
No evidence of selection for mutational robustness during lethal mutagenesis of lymphocytic choriomeningitis virus. Virology (2008) 1.01
Competition-colonization dynamics in an RNA virus. Proc Natl Acad Sci U S A (2010) 1.01
Structure of foot-and-mouth disease virus mutant polymerases with reduced sensitivity to ribavirin. J Virol (2010) 1.01
Dynamics of mutation and recombination in a replicating population of complementing, defective viral genomes. J Mol Biol (2006) 1.00
Resistance to extinction of low fitness virus subjected to plaque-to-plaque transfers: diversification by mutation clustering. J Mol Biol (2002) 0.98
Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence. J Virol (2005) 0.98
Quasispecies as a matter of fact: viruses and beyond. Virus Res (2011) 0.98
Expansion of host-cell tropism of foot-and-mouth disease virus despite replication in a constant environment. J Gen Virol (2004) 0.97
Pathways to extinction: beyond the error threshold. Philos Trans R Soc Lond B Biol Sci (2010) 0.97
Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors. J Mol Biol (2002) 0.96
Guinea pig-adapted foot-and-mouth disease virus with altered receptor recognition can productively infect a natural host. J Virol (2007) 0.93
Beneficial effects of population bottlenecks in an RNA virus evolving at increased error rate. J Mol Biol (2008) 0.93
Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection. Virology (2005) 0.92
Adaptability costs in immune escape variants of vesicular stomatitis virus. Virus Res (2005) 0.92
Minority report: hidden memory genomes in HIV-1 quasispecies and possible clinical implications. AIDS Rev (2008) 0.92
Evolution of cell recognition by viruses: a source of biological novelty with medical implications. Adv Virus Res (2003) 0.92
Lethal mutagenesis of viruses. Curr Opin Virol (2011) 0.92
Mutation hot spots in hepatitis B surface antigen in chronic carriers from Khoozestan province, southern of Iran. Iran J Allergy Asthma Immunol (2013) 0.92
The impact of quasispecies dynamics on the use of therapeutics. Trends Microbiol (2012) 0.91
Fitness increase of memory genomes in a viral quasispecies. J Mol Biol (2004) 0.91
Evidence of the coevolution of antigenicity and host cell tropism of foot-and-mouth disease virus in vivo. J Virol (2003) 0.90
Modeling viral genome fitness evolution associated with serial bottleneck events: evidence of stationary states of fitness. J Virol (2002) 0.90
Invariant aphthovirus consensus nucleotide sequence in the transition to error catastrophe. Infect Genet Evol (2005) 0.90
Repeated bottleneck transfers can lead to non-cytocidal forms of a cytopathic virus: implications for viral extinction. J Mol Biol (2007) 0.90
Molecular characterization of a dual inhibitory and mutagenic activity of 5-fluorouridine triphosphate on viral RNA synthesis. Implications for lethal mutagenesis. J Mol Biol (2008) 0.89
Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype. J Virol (2013) 0.88
Topology of evolving, mutagenized viral populations: quasispecies expansion, compression, and operation of negative selection. BMC Evol Biol (2008) 0.88
A segmented form of foot-and-mouth disease virus interferes with standard virus: a link between interference and competitive fitness. Virology (2005) 0.88
Synchronous loss of quasispecies memory in parallel viral lineages: a deterministic feature of viral quasispecies. J Mol Biol (2003) 0.88
Deletion mutants of VPg reveal new cytopathology determinants in a picornavirus. PLoS One (2010) 0.87
Fitness distributions in exponentially growing asexual populations. Phys Rev Lett (2003) 0.87
An interfering activity against lymphocytic choriomeningitis virus replication associated with enhanced mutagenesis. J Gen Virol (2009) 0.86
Few mutations in the 5' leader region mediate fitness recovery of debilitated human immunodeficiency type 1 viruses. J Virol (2005) 0.86
Minority memory genomes can influence the evolution of HIV-1 quasispecies in vivo. Gene (2006) 0.86
Influence of mutagenesis and viral load on the sustained low-level replication of an RNA virus. J Mol Biol (2011) 0.85
Biological effect of Muller's Ratchet: distant capsid site can affect picornavirus protein processing. J Virol (2009) 0.85
Memory in retroviral quasispecies: experimental evidence and theoretical model for human immunodeficiency virus. J Mol Biol (2003) 0.84
5-fluorouracil in lethal mutagenesis of foot-and-mouth disease virus. Future Med Chem (2009) 0.84
Monitoring sequence space as a test for the target of selection in viruses. J Mol Biol (2005) 0.84
Transdisciplinary EU science institute needs funds urgently. Nature (2010) 0.83
Tempo and mode of inhibitor-mutagen antiviral therapies: a multidisciplinary approach. Proc Natl Acad Sci U S A (2011) 0.83
Persistence of foot-and-mouth disease virus in cell culture revisited: implications for contingency in evolution. J Gen Virol (2008) 0.82
Analysis of sequential hepatitis A virus strains reveals coexistence of distinct viral subpopulations. J Gen Virol (2006) 0.82
Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis. PLoS One (2013) 0.81
Viral fitness can influence the repertoire of virus variants selected by antibodies. J Mol Biol (2006) 0.81
Microarray-based identification of antigenic variants of foot-and-mouth disease virus: a bioinformatics quality assessment. BMC Genomics (2006) 0.81
Identification of host and viral factors involved in a dissimilar resolution of a hepatitis C virus infection. Liver Int (2013) 0.80
Mutagenesis-mediated virus extinction: virus-dependent effect of viral load on sensitivity to lethal defection. PLoS One (2012) 0.80
Competition-colonization dynamics: An ecology approach to quasispecies dynamics and virulence evolution in RNA viruses. Commun Integr Biol (2010) 0.80
Influence of the mutant spectrum in viral evolution: focused selection of antigenic variants in a reconstructed viral quasispecies. Mol Biol Evol (2008) 0.79
Characterization of minority subpopulations in the mutant spectrum of HIV-1 quasispecies by successive specific amplifications. Virus Res (2007) 0.79
Arenaviruses and lethal mutagenesis. Prospects for new ribavirin-based interventions. Viruses (2012) 0.79
New vaccine design based on defective genomes that combines features of attenuated and inactivated vaccines. PLoS One (2010) 0.79
Evidence of Muller's ratchet in herpes simplex virus type 1. J Gen Virol (2012) 0.78
Virus evolution. Curr Opin Virol (2011) 0.78
Exploration of sequence space as the basis of viral RNA genome segmentation. Proc Natl Acad Sci U S A (2014) 0.78
Cytochrome P450 catalyzed oxidative hydroxylation of achiral organic compounds with simultaneous creation of two chirality centers in a single C-H activation step. Angew Chem Int Ed Engl (2014) 0.78
Quasispecies dynamics in hepatitis C liver transplant recipients receiving grafts from hepatitis C virus infected donors. J Gen Virol (2015) 0.78
Lethal mutagenesis of foot-and-mouth disease virus involves shifts in sequence space. J Virol (2011) 0.78
Molecular dissection of a viral quasispecies under mutagenic treatment: positive correlation between fitness loss and mutational load. J Gen Virol (2012) 0.77
Mutagen-mediated enhancement of HIV-1 replication in persistently infected cells. Virology (2012) 0.77
Directed evolution by using iterative saturation mutagenesis based on multiresidue sites. Chembiochem (2013) 0.77